Evogene (EVGN) Receives News Sentiment Score of 0.05

News articles about Evogene (NYSE:EVGN) have trended somewhat positive on Monday, Accern Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Evogene earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 25 out of 100, indicating that recent media coverage is very unlikely to have an impact on the stock’s share price in the near term.

Shares of Evogene (NYSE EVGN) traded up 0.5217% during midday trading on Monday, hitting $4.8753. 35,525 shares of the stock were exchanged. Evogene has a 52-week low of $4.65 and a 52-week high of $7.09. The firm’s 50 day moving average price is $5.15 and its 200-day moving average price is $5.19. The stock’s market cap is $124.93 million.

Evogene (NYSE:EVGN) last announced its quarterly earnings data on Wednesday, May 17th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.18) by $0.01. The company had revenue of $0.72 million for the quarter. Evogene had a negative net margin of 235.47% and a negative return on equity of 18.60%. On average, equities research analysts expect that Evogene will post ($0.66) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Evogene (EVGN) Receives News Sentiment Score of 0.05” was first published by WKRB News and is the sole property of of WKRB News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.wkrb13.com/markets/2285753/evogene-evgn-receives-news-sentiment-score-of-0-05.html.

About Evogene

Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd.

Insider Buying and Selling by Quarter for Evogene (NYSE:EVGN)

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2285753/evogene-evgn-receives-news-sentiment-score-of-0-05.html

Receive News & Ratings for Evogene Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene Ltd and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

© 2006-2017 WKRB News.